WW domain containing oxidoreductase, designated WWOX, FOR or WOX1, is a known pro-apoptotic factor when ectopically expressed in various types of cancer cells, including glioblastoma multiforme (GBM). The activation of sonic hedgehog (Shh) signaling, especially paracrine Shh secretion in response to radiation, is associated with impairing the effective irradiation of cancer cells. Here, we examined the role of Shh signaling and WOX1 overexpression in the radiosensitivity of human GBM cells. Our results showed that ionizing irradiation (IR) increased the cytoplasmic Shh and nuclear Gli-1 content in GBM U373MG and U87MG cells. GBM cells with exogenous Shh treatment exhibited similar results. Pretreatment with Shh peptides protected U373MG and U87MG cells against IR in a dose-dependent manner. Cyclopamine, a Hedgehog/Smoothened (SMO) inhibitor, reversed the protective effect of Shh in U87MG cells. Cyclopamine increased Shh plus IR-induced H2AX, a marker of DNA doublestrand breaks, in these cells. To verify the role of Shh signaling in the radiosensitivity of GBM cells, we tested the effect of the Gli family zinc finger 1 (Gli-1) inhibitor zerumbone and found that it could sensitize GBM cells to IR. We next examined the role of WOX1 in radiosensitivity. Overexpression of WOX1 enhanced the radiosensitivity of U87MG (possessing wild type p53 or WTp53) but not U373MG (harboring mutant p53 or MTp53) cells. Pretreatment with Shh peptides protected both WOX1-overexpressed U373MG and U87MG cells against IR and increased the cytoplasmic Shh and nuclear Gli-1 content. Zerumbone enhanced the radiosensitivity of WOX1-overexpressed U373MG and U87MG cells. In conclusion, overexpression of WOX1 preferentially sensitized human GBM cells possessing wild type p53 to radiation therapy. Blocking of Shh signaling may enhance radiosensitivity independently of the expression of p53 and WOX1. The crosstalk between Shh signaling and WOX1 expression in human glioblastoma warrants further investigation.
Introduction
Glioblastoma multiforme (GBM), also known as a WHO grade IV astrocytoma, is one of the most lethal brain malignancies in adults. 1 Despite aggressive surgical resection and adjuvant intensified radiation therapy, even concurrent with chemotherapy, the five-year overall survival prognosis for GBM patients remains poor at less than 10%. 2 Treatment resistance and a high recurrence rate are the main causes of death in GBM patients. It is important to search for novel targets and develop molecular-targeted therapeutic regimens for further treatment of GBM.
Sonic hedgehog (Shh) is a signaling protein discovered in Drosophila that plays a critical role during embryogenesis. The Shh signaling pathway regulates the proliferation and differentiation of various types of stem cells. 3, 4 It mediates the activation of the transcription factors of the Gli family. Upon activation, Gli proteins translocate into the nucleus from the cytosol and activate target gene transcription to control the cell cycle, cell adhesion, signal transduction, angiogenesis, and apoptosis. 5 Shh signaling and the release of paracrine in response to IR have been demonstrated to be protective against IR in hepatocellular carcinoma cells. 6 Nuclear Gli-1 overexpression correlated with primary tumor size, lymphatic metastasis, and tumor recurrence in patients with oral cavity squamous cell carcinoma that received surgery and radiotherapy. 7 The WW domain containing oxidoreductase gene (WOX1) has been studied in various kinds of cancer cells. [8] [9] [10] The WOX1 protein has been shown to be a tumor suppressor with pro-apoptotic properties, and it can work synergistically to induce apoptosis with p53. 8, 11 The expression of WOX1 is known to be altered in multiple malignancies, such as non-small cell lung carcinoma, 12 gastric carcinoma, 13 pancreatic carcinoma, 14 and invasive breast carcinoma. 15 The restoration of the WOX1 gene could prevent the growth of multiple cancers, such as lung cancer 16 and pancreatic cancer. 17 In treatment evaluation, the overexpression of WOX1 preferentially inhibited cell viability and induced apoptosis in human glioblastoma U373 MG cells expressing mutant p53 via a mechanism independent of the intrinsic apoptotic pathway. 18 p53 is a well known tumor suppressor. The N-terminal proline-rich region and the C-terminal basic region are essential for p53 to mediate apoptosis. 19 It has been previously reported that p53 can interact with WOX1 on the WW domain via its proline-rich region, 20 and the stabilization of phosphorylated p53 by WOX1 is essential for p53-mediated cell death. 21 For radiotherapy effectiveness, the presence of mutant p53 has been reported to be an unfavorable prognostic factor in glioma cells. 22 Collectively, the status of WOX1 and p53 may have a role in modulating treatment susceptibility in glioma cells.
In clinical practice, clarifying the role of each therapeutic factor may help in the development of biomarkers and therapeutic targets for patients. Given that WOX1 and Shh signaling could modulate the IR sensitivity of glioma cells for treatment, the functional interactions of WOX1 with the component(s) of the Shh signaling may have a significant clinical potential for the development of new strategies to treat GBM.
In this study, we examined the role of Shh signaling and WOX1 overexpression in the radiosensitivity of human GBM cell lines that have different p53 statuses. 
Materials and methods

Cell lines and transfection
Human glioblastoma cell lines, U87MG and U373MG, were cultured in a DMEM medium supplemented with 10% fetal bovine serum at 37 C and humidified with 5% CO 2 . Cells were transfected with pEGFPC1 (Clontech Laboratories, Inc., Palo Alto, California, USA) and human WOX1-pEGFPC1 using a jetPEI TM transfection reagent (Polyplus Transfection, Illkrich, France). The cells were sorted by GFP fluorescence expression using flow cytometry before performing further experiments.
Immunofluorescence staining
Cells were seeded on cover slips in a 24-well plate. For immunofluorescence staining, the cells were fixed by cold methanol and blocked by 5% bovine serum albumin. The cells on the cover slips were incubated with a specific antibody against Shh and Gli-1 (Santa Cruz Biothechnology, CA, USA) for 1 h at room temperature. After washing, the cells were then incubated with anti-mouse FITC-conjugated secondary antibodies (1:100; Molecular Probes, Eugene, OR, USA). The cover slips were mounted with VECTASHIELD Mounting Medium containing DAPI (Vecta Laboratories, Burlington, CA, USA).
Shh treatment and radiation delivery
Cells were pretreated with various doses (10 pg/mL-1 ng/ mL) of Shh for 24 h. After washing, the cells were irradiated with graded doses (sham RT, 1, 2 and 4 Gy) of 6 MeV of electron beam energy delivered by a linear accelerator (Clinac Õ 1800, Varian Associates, Inc., CA.; dose rate 2.4 Gy/min) in a single fraction. Full electron equilibrium was ensured for each fraction by using a parallel plate PR-60C ionization chamber (CAPINTEL, Inc., Ramsey, NJ, USA). After radiation, cells were plated for the colony formation assay.
Colony formation assay
Viable tumor cells (10 3 ) were plated into separate 35-mm culture dishes to grow in McCoy's 5 A medium containing 20% heat-inactivated fetal bovine serum and 0.24% agarose at 37 C in a humidified 5% CO 2 incubator. After 10-14 days, the dishes were stained with crystal violet, and colonies containing more than 50 cells were counted. The surviving fraction was calculated as mean colonies (cells inoculated Â plating efficiency). The control plating efficiency for U87MG and U373MG cells was approximately 63% and 55%, respectively. Survival curves were plotted by a linear-quadratic model as previously described. 6 D0 values (radiation dose with 37% survival) for control, Shh, cyclopamine and cyclopamine plus Shh were 4.7 Gy, 9.6 Gy, 4.7 Gy and 5.1 Gy, respectively. Cells were plated for colony formation assay after radiation. After 10-14 days, the dishes were stained with crystal violet, and colonies containing !50 cells were counted. Data from three separate experiments were expressed as mean AE standard error of mean. D0 values (radiation dose with 37% survival) for control, Shh, cyclopamine and cyclopamine plus Shh were 4.7 Gy, 9.6 Gy, 4.7 Gy and 5.1 Gy, respectively Immunofluorescence for Shh, Gli-1, and gamma-H2AX expression For the immunofluorescence assay, cells were harvested, washed, blocked, and stained with primary rabbit antihuman polyclonal antibodies against Shh and Gli-1 (Santa Cruz Biothechnology, CA, USA), followed by the secondary antibody rhodamine red-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). For the detection of DNA double-strand breaks with gamma-H2AX antibody, we used primary mouse anti-human monoclonal Ab against gamma-H2AX (Abcam, Cambridge, MA, USA), followed by the secondary CytTM-2-conjugated donkey anti-mouse IgG (Jackson Immuno-Research Laboratories, West Grove, PA, USA). Hoechst 33342 (Sigma-Aldrich, St. Louis, MO, USA) was used for nuclear counterstaining before mounting.
Cell images were obtained using an Olympus fluorescence microscope.
Calculation for sensitizer enhancement ratios
The sensitizer enhancement ratio (SER) was calculated as the radiation dose needed for radiation alone divided by the dose needed for various treatments plus radiation at a survival fraction of 37% (D 0 in radiobiology).
Results
Shh signaling and radiosensitivity in human glioblastoma cells
Ionizing irradiation (IR) increased the cytoplasmic Shh and nuclear Gli-1 content in GBM U373MG and U87MG cells Figure 1) , with an immunofluorescence assay used to obtain a semi-quantiation estimation. Exogenous Shh treatment exhibited similar results on the expression of Shh and Gli-1 (Figure 1 ). Pretreatment with the N-terminal Shh peptide protected U373MG and U87MG cells against IR with increased survival in a dose-dependent manner (Figure 2) . A mechanistic assay showed that cyclopamine, an SMO inhibitor, reversed the protective effect of Shh in U87MG cells (Figure 3) . Cyclopamine increased the expression of Shh plus IR-induced g-H2AX, a marker of DNA double-strand break, in these cells (Figure 4) according to the immunofluorescence assay. To further assess the role of Shh signaling in the radiosensitivity of GBM cells, we tested the radiosensitizing effect of the Gli-1 inhibitor zerumbone. The results showed that zerumbone sensitized U373MG and U87MG cells to IR ( Figure 5 ).
WOX1 overexpression enhanced radiosensitivity in U87MG cells
The overexpression of WOX1 enhanced the radiosensitivity of U87MG (possessing wild type p53) in comparison with parental U87MG cells (Figure 6a ). In U373MG cells harboring mutant p53, the overexpression of WOX1 had no significant effect on radiosensitivity (Figure 6b ).
Shh signaling affected the radiosensitivity of glioblastom cells independent of WOX1 expression
Treatment with an Shh peptide prior to IR protected both WOX1-overexpressed U373MG and U87MG cells survival) of U373MG cells with and without WOX1 overexpression were 3.6 Gy and 3.7 Gy, respectively. Cells were plated for colony formation assay after radiation. After 10-14 days, the dishes were stained with crystal violet, and colonies containing !50 cells were counted. Data from three separate experiments were expressed as mean AE standard error of mean against IR (Figure 7 ) and decreased the expression of g-H2AX ( Figure 8 ). Zerumbone enhanced the radiosensitivity of WOX1-overexpressed U373MG and U87MG cells (Figure 9 ).
Discussion
During skin tumorigenesis, transient overexpression of WOX1 occurs in the initial stage, followed by downregulation as the tumor grows. 23, 24 Up to date, whether the transiently overexpressed WOX1 induces apoptosis of cancer cells is largely unknown. 18, 25 Shh signaling involves carcinogenesis, drug resistance, and poor prognosis of various types of cancers. [26] [27] [28] In this study, we determined that IR might activate Shh signaling to protect cancer cells. Accordingly, synthetic Shh peptides protected human glioblastoma cells from IR-mediated death. The radioprotective effect of the Shh peptides was noted in both parental and WOX1-overexpressed glioblastoma cells and could be reversed by an Shh signaling inhibitor. WOX1 overexpression preferentially sensitized glioblastoma cells possessing wild type p53.
Given that p53 expression enhances intrinsic radiosensitivity, 29, 30 the differential radiosensitizing effect of WOX1 overexpression in wild type p53 U87MG cells, but not p53 mutant U373MG cells, may involve interactions between the p53 and WOX1 in human glioblastoma cells. We have determined that U373MG cells are more sensitive to apoptosis induced by temozolomide. 18 It is interesting that the correlation between WOX1 expression and sensitivity to temozolomide or IR is different and this issue warrants further investigations.
The crosstalk between WOX1 expression and Shh signaling has not been reported. In this study, we have demonstrated for the first time that Shh peptides counteracted the ectopic WOX1-mediated enhancement of radiosensitivity. Furthermore, the inhibitor of Shh signaling zerumbone sensitized glioblastoma cells in both parental and ectopic WOX1-expressing glioblastoma cells. The observation implies that Shh signaling may counteract the radiosensitizing effect of WOX1 overexpression.
Radiation could induce DNA double-strand break and the capacity of cells to repair lethal DNA damages is regarded as a significant factor of radiosensitivity. In this study, we found that radiation-induced DNA doublestrand break, with g!-H2AX as a marker, could be repaired within 6 h after radiation. Exogenous addition of shh peptide shortened the repair time and inhibition of shh signaling reversed this effect in both parental and WOX1expressing glioblastoma cells. Enhancement of repair for DNA double-strand break might be an important event induced by shh signaling of glioblastoma cells.
The Shh signaling inhibitors used in this study included the SMO inhibitor cyclopamine and the Gli-1 inhibitor zerumbone. Because of their radiosensitizing effects on glioblastoma cells noted in this study, the potential application of these inhibitors in radiotherapy for glioblastoma could be further investigated.
In conclusion, transient overexpression of WOX1 may preferentially sensitize human wild type p53-positive glioblastoma cells to radiation therapy. Blocking the Shh signaling enhances the radiosensitivity of GBM cells independent of the levels of p53 and WOX1. However, WOX1 interaction with a single or multiple components in the Shh signaling in human glioblastoma cells remains to be established.
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